In collaboration with researchers across the University of Colorado, Anschutz Medical Campus - CU Gynecologic Oncology researchers published a paper this week in the Clinical Cancer Research that shares findings from research looking at how the composition of ovarian cancer tumors changes during chemotherapy and contributes to therapeutic response.
Our ultimate goal is that someone who is diagnosed with ovarian cancer would be able to come in and we would be able to take the primary tumor and use the two major technologies described in the research study, transcriptomics using Nanostring and multi-spectral immunohistochemistry (IHC), to get an idea about what is being expressed and what the tumor microenvironment looks like.Benjamin Bitler, PhD